Ajinomoto CELLiST Korea participates in KOREA PHARM & BIO 2024

페이지 정보

작성자ajinomo 조회 307 작성일 24-04-11 11:36



Providing information on ‘BASAL CHO MX’, ‘F7’ and new product ‘HEK293 Vaccine media/Gene therapy’

Ajinomoto CELLiST Korea, a cell culture medium development and manufacturing company, announced that it will participate in ‘KOREA PHARM & BIO 2024 (International Pharmaceutical and Bio Industry Exhibition)’ held at KINTEX. (Ilsan-KINTEX Exhibition Hall 2 HALL 7~8, 7H202 booth)

KOREA PHARM & BIO 2024 is the 14th event this year and will be held at KINTEX Exhibition Hall 2 for 4 days from April 23rd to 26th. Major exhibitions include pharmaceuticals/raw materials, health functional food ingredients and materials, biopharmaceuticals, consignment services and outsourcing, analysis/consulting/services, smart healthcare, pharmaceutical/bio new technologies, and pharmaceutical/bio-related research institutes/collaborating organizations/media. It consists of eight fields and events such as special exhibitions, national pavilions, side events, and conferences.

At this exhibition, Ajinomoto CELLiST Korea provides information on the newly released cell culture media ‘BASAL CHO MX’ and ‘F7’, as well as the ‘HEK293 Vaccine media/Gene Therapy media’ product, which is scheduled to be released.

BASAL CHO MX is a cell culture medium developed through collaboration between 'KBI Biopharma' of the United States, 'JSR Life Sciences' of Japan, and Ajinomoto Cellist Korea. It is based on the CHO-M cell line (a CHO-K1-based cell line from Selexis). developed. This product can be used on all CHO cell lines and can be expected to improve culture performance. F7 is a feed media developed to significantly improve performance by using Ajinomoto Group's proprietary cysteine stabilization technology to ensure a stable and continuous supply of cysteine at high concentrations to CHO cells throughout culture.

There are two types of media dedicated to HEK293 cells that are scheduled to be released: HEK293 Vaccine media, which is suitable for producing viral vaccines, and HEK293 Gene therapy media, which is intended for gene therapy. We are currently distributing samples to Ajinomoto CELLiST Korea customers and are preparing for market launch, and we plan to introduce these products and propose samples to many new customers through this exhibition.

An official from Ajinomoto CELLiST Korea said, “We are happy to participate in this expo, where development, manufacturing, and distribution can all be held in one place every year, and to promote the cell culture medium technology we have accumulated so far and new products scheduled to be released.” He added, “We will continue to develop our technology in the future.” “We will strive to expand our business to support customized products along with promotions,” he said.

Meanwhile, Ajinomoto CELLiST Korea has been supplying cell culture media for biopharmaceuticals with excellent production capabilities, including high-quality amino acids, under the brand ‘CELLiST’, which was created through over 30 years of accumulated research.



등록된 댓글이 없습니다.


Start typing and press enter!